VANCOUVER, B.C.—Two different monoclonal antibodies targeting the interleukin-23 p19 subunit achieved all of their efficacy end points in their respective placebo-controlled, phase 3 induction trials of ulcerative colitis patients with advanced and largely refractory disease.
In the QUASAR trial, response rates in patients taking guselkumab (Tremfya, Janssen) were still rising for all of the primary and secondary efficacy end points at the end of 12 weeks, according to investigator Gary R.